ELDNEledon Pharmaceuticals, Inc.同业对比
Eledon Pharmaceuticals, Inc. 与SIC 2834 行业的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:同 SIC 行业分类 | 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ELDN本股 | $218M#10 | — | 6.6x#13 | — | — | -26.1%#11 | — | -138.2%#13 | — | — | 10.5%#4 | — |
| ALXO | $245M#2 | — | 1.8x#10 | — | — | 24.6%#6 | — | -74.7%#9 | -84.4%#2 | — | — | — |
| CAMP | $242M#3 | — | — | 69.2x#7 | 436.5%#2 | -55.2%#13 | -1502.4%#6 | — | — | — | — | — |
| RNAC | $242M#4 | — | — | 605.1x#9 | -99.0%#8 | -68.3%#15 | -35851.3%#9 | — | — | — | — | — |
| WHWK | $237M#5 | — | 1.3x#5 | 33.1x#6 | -72.5%#7 | 67.7%#4 | -1601.1%#7 | -11.3%#5 | — | — | 111.7%#2 | — |
| NATR | $232M#6 | 13.2x#2 | 1.7x#9 | 0.5x#1 | 5.7%#5 | 153.7%#2 | 5.2%#3 | 14.3%#2 | — | 9#1 | -19.8%#5 | — |
| ZNTL | $226M#7 | — | 1.6x#7 | — | -100.0%#9 | 17.4%#7 | — | -95.4%#11 | — | — | — | — |
| SIGA | $221M#8 | — | 1.3x#6 | 2.3x#3 | -31.8%#6 | -60.7%#14 | 25.1%#2 | 14.1%#3 | — | — | -57.6%#8 | 19.5%#1 |
| KROS | $219M#9 | — | 0.8x#1 | 0.9x#2 | 6775.0%#1 | 146.4%#3 | 27.7%#1 | 33.2%#1 | — | — | -29.2%#6 | — |
| BRVE | $2.6B#1 | — | — | — | — | — | — | — | — | — | — | — |
| NKTX | $209M#11 | — | 0.8x#2 | — | — | 4.3%#9 | — | -42.0%#6 | — | — | 51.8%#3 | — |
| KRRO | $208M#12 | — | 2.0x#11 | 32.5x#5 | 181.5%#3 | -40.3%#12 | -1906.4%#8 | -113.6%#12 | -155.2%#3 | — | -54.3%#7 | — |
| TNXP | $200M#14 | — | 0.9x#3 | 15.3x#4 | 29.8%#4 | 4.6%#8 | -959.1%#5 | -55.8%#8 | -234.8%#4 | — | -57.8%#9 | — |
| ANTX | $198M#15 | — | 2.6x#12 | — | — | 31.5%#5 | — | -46.3%#7 | — | — | 306.2%#1 | — |
| PEPG | $202M#13 | — | 1.7x#8 | — | — | 0.4%#10 | — | -75.0%#10 | — | — | — | — |
| ORMP | $194M#16 | 1.1x#1 | 1.0x#4 | 97.1x#8 | — | 573.1%#1 | -754.4%#4 | 0.0%#4 | -4.4%#1 | — | — | — |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。 本表构建超时,仅覆盖该组的一部分成员;排名仅相对于已列出的行,稍后会自动补全。 数据构建于 2026-09-17。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议